Actnova Secures $3M Funding for Breakthrough AI-driven Animal Behavior Analysis Platform
Reading Time: 2 minutesActnova, a Korean AI SaaS solution developer, the brains behind the animal behavior testing platform ‘Actverse,’ has secured a noteworthy KRW 3.3 billion($3M) in pre-series A funding. Led by Hana Ventures, the investment also saw participation from A Ventures and Fast Ventures.
Notably, Actnova, a spin-off from KAIST, had previously received a KRW 500 million seed investment from Kakao Ventures in 2022, and selected the TIPS program in 2023.
Actnova utilizes AI and web platform technologies to analyze behavioral symptoms in animal models, primarily focusing on the development of treatments for brain disorders like dementia and Parkinson’s disease. The recent funding will support Actnova’s global expansion, product launches, and collaborations with research institutes and pharmaceutical companies. The company’s innovative approach involves leveraging machine learning to quantify complex behaviors, traditionally challenging to measure, significantly automating the symptom diagnosis process.
This investment aligns with Actnova’s strategic emphasis on collaborations with MIT and the Broad Institute, international market entry, and the growing interest from global customers in its SaaS products.
Actnova’s technology has already found applications in research collaborations with institutions such as the Korea Brain Research Institute and Daegu Medivalley, underscoring its potential in real-world research settings.
Hana Ventures stressed the rising demand for objective information and quantification through the automated analysis of animal behavior, citing Actnova’s significant references across global academia and industry.
Actnova’s CEO, Kim Dae-geon, expressed gratitude for securing substantial investment in a challenging environment, highlighting the potential to position the company as a global startup within the Korean biotech industry.
[Korean bioHealth Startups News]
- MedInTech Secures 20 billion KRW Series B Investment for Innovative Medical Endoscope
- Korea’s MSS Hosts Korea-Japan Bio Ecosystem Roundtable: Fostering Collaboration Between Both Nations
- ‘RADICURE’ Secures pre-Series A funding for Innovative Digital X-ray Dementia Treatment
- Dreampac Secures Funding to Develop PIPAC for Treating Peritoneal Carcinomatosis
- Rexpharm Forms MOU with Timely Basket to Develop and Distribute Health Foods in U.S.
- SEOUL BIOHUB Global Center Opens, Aiming to Boost Global BioTech Competitiveness
- Delight Room Invests in Soundable Health for Advanced Sound Analysis in Healthcare
- Apollon Secures 2.3 Billion KRW in Funding for Innovative Needle-Free CGM Technology
- Korean Space Medicine Startup SpaceLiintech Lands 4 Billion KRW Series A Funding
- ArtBlood Secures KRW 6.5 Billion in Series A for Synthetic Blood Production
[Korean Startup Weekly News #4] Hey Dealer Raises KRW 45 Billion to Transform Korea’s Used Car Market – 와우테일(WOWTALE)
[…] Actnova Secures $3M Funding for Breakthrough AI-driven Animal Behavior Analysis PlatformKorean AI firm Actnova secures $3M pre-series A funding for its Actverse platform, focusing on animal behavior analysis in drug development. […]